Predict your next investment

Edwards Lifesciences company logo
Corporation
HEALTHCARE | Medical Devices & Equipment
edwards.com

See what CB Insights has to offer

Investments

18

Portfolio Exits

2

Funds

1

Partners & Customers

5

About Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) is a medical equipment and devices company that designs, manufactures, and markets tissue heart valves and related repair products. The company also provides solutions in enhanced surgical recovery, clot management, infection control, anesthesia, hospital administration, annuloplasty rings, catheters, hemodynamic monitoring, and more.

Edwards Lifesciences Headquarters Location

One Edwards Way

Irvine, California, 92614,

United States

949-250-2500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Edwards Lifesciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Edwards Lifesciences in 3 Expert Collections, including Medical Devices.

M

Medical Devices

4,284 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health Monitoring & Diagnostics

313 items

Companies developing technology for computer-aided diagnostic imaging. Companies tagged as #ComputerAidedDxImaging

H

Health IT

360 items

Edwards Lifesciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Edwards Lifesciences Rank

Latest Edwards Lifesciences News

08:30 EDT EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

Aug 17, 2022

News provided by Share this article Share this article IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW ), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR). Edwards Lifesciences' PASCAL Precision transcatheter valve repair system "Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat the large population of patients with mitral and tricuspid valve disease," said Bernard J. Zovighian, Edwards' corporate vice president, transcatheter mitral and tricuspid therapies. "Edwards has a long history of innovation, and the significant advancements in the PASCAL Precision system are designed to improve clinicians' ability to provide positive outcomes for patients with both MR and TR." The PASCAL Precision system is utilized in the treatment of patients with mitral or tricuspid regurgitation, through a single delivery system. The new system is designed to enable precise navigation and implant delivery. "The PASCAL Precision system provides significant advancements in operator experience with implant delivery," said Prof Jörg Hausleiter, Professor of Medicine and the Deputy Clinic Director at the Ludwig-Maximilians University in Munich, Germany. "Having successfully treated my first patient with the PASCAL Precision system, I found it easy to operate and the improved catheter response and stability gave me greater control to place the implant exactly where I needed to." The PASCAL Precision system includes PASCAL and PASCAL Ace implants, which feature independent grasping, atraumatic clasp and closure, and implant versatility including the ability to elongate and navigate complex anatomy. The PASCAL Precision system is one of multiple transcatheter repair or replacement therapies in development by Edwards that are designed to address mitral and tricuspid valve diseases. The company is committed to transforming the treatment of mitral and tricuspid patients, supported by a robust body of clinical evidence. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2021, and its Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2022. These filings, along with important safety information about our products, may be found at Edwards.com. Edwards, Edwards Lifesciences, the stylized E logo, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, PASCAL Ace, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. SOURCE Edwards Lifesciences Corporation

Edwards Lifesciences Investments

18 Investments

Edwards Lifesciences has made 18 investments. Their latest investment was in egnite as part of their Seed on February 2, 2021.

CBI Logo

Edwards Lifesciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/10/2021

Seed

egnite

Yes

2

9/23/2020

Series C - II

V-Wave

$28M

No

2

7/15/2020

Series B

Caption Health

$53M

Yes

5

4/26/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

4/13/2016

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/10/2021

9/23/2020

7/15/2020

4/26/2018

4/13/2016

Round

Seed

Series C - II

Series B

Series C

Series A - II

Company

egnite

V-Wave

Caption Health

Subscribe to see more

Subscribe to see more

Amount

$28M

$53M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

5

10

10

Edwards Lifesciences Portfolio Exits

2 Portfolio Exits

Edwards Lifesciences has 2 portfolio exits. Their latest portfolio exit was Middle Peak Medical on February 14, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/14/2017

Acquired

$99M

1

9/21/2007

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

2/14/2017

9/21/2007

Exit

Acquired

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

1

0

Edwards Lifesciences Acquisitions

13 Acquisitions

Edwards Lifesciences acquired 13 companies. Their latest acquisition was Corvia Medical on March 11, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/11/2019

Series E+

$99M

$108.28M

Acquired

2

11/29/2018

$99M

Acquired Unit

1

11/26/2018

$99M

Acquired Unit

1

4/18/2018

Subscribe to see more

$99M

Subscribe to see more

10

12/6/2017

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

3/11/2019

11/29/2018

11/26/2018

4/18/2018

12/6/2017

Investment Stage

Series E+

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$108.28M

$99M

Note

Acquired

Acquired Unit

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Edwards Lifesciences Fund History

1 Fund History

Edwards Lifesciences has 1 fund, including Social Impact Investment Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/2/2021

Social Impact Investment Fund

$70M

1

Closing Date

8/2/2021

Fund

Social Impact Investment Fund

Fund Type

Status

Amount

$70M

Sources

1

Edwards Lifesciences Partners & Customers

5 Partners and customers

Edwards Lifesciences has 5 strategic partners and customers. Edwards Lifesciences recently partnered with UPS on May 5, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

5/4/2020

Vendor

United States

UPS Supports Edwards Lifesciences' Distribution Of Critical ICU Monitoring Equipment And Other Medical Technologies

UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 .

3

12/10/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/29/2015

Vendor

United States

Subscribe to see more

Subscribe to see more

10

11/24/2004

Licensor

Netherlands

Subscribe to see more

Subscribe to see more

10

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

5/4/2020

12/10/2018

6/29/2015

11/24/2004

Type

Vendor

Partner

Vendor

Licensor

Licensor

Business Partner

Country

United States

United States

United States

Netherlands

United States

News Snippet

UPS Supports Edwards Lifesciences' Distribution Of Critical ICU Monitoring Equipment And Other Medical Technologies

UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Edwards Lifesciences Team

14 Team Members

Edwards Lifesciences has 14 team members, including current Chief Executive Officer, Michael A. Mussallem.

Name

Work History

Title

Status

Michael A. Mussallem

Chief Executive Officer

Current

David Pyott

Chief Executive Officer

Current

Thomas M Abate

Chief Financial Officer

Current

Anita B. Bessler

Chief Financial Officer

Current

Arie Rand

Delta Three, Top Image Systems, and Delta Galil Industries

Chief Financial Officer

Current

Name

Michael A. Mussallem

David Pyott

Thomas M Abate

Anita B. Bessler

Arie Rand

Work History

Delta Three, Top Image Systems, and Delta Galil Industries

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer

Chief Financial Officer

Status

Current

Current

Current

Current

Current

You May Also Like

Sensome Logo
Sensome

Sensome develops micro-sensor technology for smart medical devices. Sensome's sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body and machine learning algorithms for accurate and predictive real-time analysis.

Bigfoot Biomedical Logo
Bigfoot Biomedical

Bigfoot Biomedical is on a mission to improve the lives of people with insulin-requiring diabetes through the application of smart technology. Bigfoot's approach includes delivering an Internet-of-Things medical device, a cloud-connected system bundled as a monthly subscription service, to a broad population historically challenged by the high upfront costs of traditional insulin delivery hardware.

Implandata Ophthalmic Products Logo
Implandata Ophthalmic Products

Implandata Ophthalmic Products offers the EYEMATE system to empower people to take control of glaucoma – anytime and anywhere. EYEMATE is an AI-powered, cloud-based, data-centric platform for 24/7/365 monitoring and predictive modeling of disease progression. EYEMATE's data analytics combine IOP with other vital parameters to enable personalized therapies. For people with glaucoma, this means improved quality of life and peace of mind. For eye doctors, this means improved patient care at a significantly lower cost.

CeQur Logo
CeQur

CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.

Nonin Medical Logo
Nonin Medical

Nonin Medical is a medical device company. It had developed the Pulse Oximeter. Nonin Medical offers non-invasive patient monitoring systems including fingertip and tabletop pulse oximeters, regional oximetry, capnography, near-infrared spectroscopy and BIS monitors.

Withings Logo
Withings

Withings creates smart products and apps to help people across the world take care of their health and well-being. By extending the capabilities of an object through network resources, Withings provides access to computing and storage facility at no extra cost, turning objects into smart connected devices.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.